Company intelligence / Profile preview

Donggu Biopharmaceutical

Ownership: Private
Development stage: Other

Overview

Donggu Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative therapies for metabolic diseases. The company focuses on multi-target agonists, particularly targeting GLP-1, GIP, and Glucagon receptors to treat conditions such as obesity, type 2 diabetes, and MASH (formerly NASH). Their lead programs include long-acting peptide analogs designed to improve metabolic health and weight loss outcomes. Donggu Biopharmaceutical leverages advanced peptide engineering and formulation technologies to create differentiated treatments in the highly competitive metabolic space.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Donggu Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Donggu Biopharmaceutical.

Explore the full profile